the product in the database has an inactive status
indications:
Treatment of small veins and telangiectasia (vascular spider veins) by injection as part of sclerotherapy.
Composition:
1 ml solution for injection contains 2 mg or 10 mg tetradecyl sodium sulphate.
Action:
A sclerosing agent for topical injections. Tetradecyl Sodium Sulfate causes damage to endothelial cells in the lumen of the vein into which the injection is made. The purpose of compression sclerotherapy is to compress the vein to minimize the resulting thrombus; and then the formation of scar tissue in the vein leads to the formation of fibrosis and permanent occlusion of the vessel. Lack of vein compression allows for a greater thrombus, resulting in less fibrosis in the vein.
Contraindications:
Hypersensitivity to tetradecyl sodium sulfate or to any of the preparation ingredients. Traffic disability for any reason. Patients currently using oral contraceptives. Significant obesity. acute thrombophlebitis. Local or systemic infection. Varicose caused by tumors located in the pelvic region or in the abdominal cavity. An uncontrollable systemic disease, e.g. diabetes. Surgical valve insufficiency requiring surgical treatment.
Precautions:
Before the injection, an in-depth assessment of the performance of valves and patency of the deep veins should be performed. Particular caution in terms of needle insertion and slow injection of the minimum effective volume in each injection site are essential for safe and effective treatment. Before starting treatment, a medical history of allergies should be performed in all patients. In cases where extreme caution is indicated, give a test dose of 0.25 ml to 0.5 ml of the preparation within 24 hours before further treatment. Special care should be taken in patients with arterial disease, such as severe atherosclerosis of the peripheral arteries or thromboangiitis obliterans (Bürger's disease) and when injecting above and behind the medial ankle (risk for the posterior tibial artery). The likelihood of pigmentation may be greater if blood extravasation occurs at the injection site (especially in the treatment of veins with a smaller area) and no pressure is applied. Do not use the product in children.
Pregnancy and lactation:
Only use during pregnancy if clearly necessary to relieve symptoms, or if the potential benefits outweigh the potential risks to the fetus (no data). It is not known whether tetradecyl sodium sulphate is excreted in human milk. When using the drug in breast-feeding women be careful.
Side effects:
There may be side effects - local: pain or burning, pigmentation of the skin, in the case of extravasation, tissue necrosis and ulcer may occur and if the injection affects the skin nerve, paresthesia and sensation may occur; vascular: superficial thrombophlebitis, deep vein thrombosis and pulmonary embolism (very rare); systemic reactions: allergic reactions (rarely local or generalized rash, urticaria, nausea or vomiting, asthma and collapse of the vessel), anaphylactic shock (may be fatal, extremely rare). Cases of migraine and transient visual disturbances have been reported. Very rarely, accidental injections into the artery (mainly posterior tibial artery above the medial malleolus) have been observed, which may lead to gangrene.
Dosage:
Intravenously. Adults: 0.1-1 ml of the preparation at a dose of 2 mg / ml or 0.25-1 ml of the preparation at a dose of 10 mg / ml, injected in each place, a maximum of 10 ml.
(C)
